2. Infection

Infection

Infection

Related Products

PDF 70.44 MB

Infection is a pathophysiological process that involves the invasion and colonization of a living organism (host) by disease-causing infectious agents, the reaction of host tissues to these agents and the toxins they produce, and the transmission of infectious agents to other hosts. Common infectious agents include viruses, viroids, prions, bacteria, nematodes, arthropods, and other macroparasites such as tapeworms. Hosts can fight infections using their immune system. Mammals often engage both innate and adaptive immune systems to eliminate infectious agents or inhibit their growth and transmission. When infection occurs, anti-infective drugs can suppress the infection. Several broad types of anti-infective drugs exist, depending on the type of organism targeted; they include antibacterial (antibiotic), antiviral, antifungal and antiparasitic agents.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-181286
    ETX1975-3 98%
    ETX1975-3 is an orally active inhibitor and bactericide targeting the bd cytochrome oxidase of Mycobacterium tuberculosis. ETX1975-3 disrupts electron transfer between the b-heme centers of the target enzyme, and in combination with Q203 (HY-101040), exerts bactericidal activity against both replicating and non-replicating Mycobacterium tuberculosis, and reduces bacterial loads in acute mouse models. ETX1975-3 retains activity against clinical isolates of multidrug-resistant/extensively drug-resistant Mycobacterium tuberculosis and non-tuberculous mycobacteria, while possessing favorable preclinical ADMET properties. ETX1975-3 can be used in studies related to tuberculosis and non-tuberculous mycobacterial infections.
    ETX1975-3
  • HY-181347
    GLPG3808 2346450-55-1 98%
    GLPG3808 is an orally active PAPD5/7 inhibitor. GLPG3808 inhibits the expression of HBcAg in various cells infected with HBV. GLPG3808 reduces the hepatitis B surface antigen levels in HBV-infected animal models. GLPG3808 can be used for the research of hepatitis B virus infection.
    GLPG3808
  • HY-181352
    SB-140
    SB-140 is a selective, covalent PLpro inhibitor with an IC50 of ≤2.5 nM against SARS-CoV-2 PLpro. SB-140 has antiviral activity against SARS-CoV-2, MERS-CoV and SARS-CoV-1.
    SB-140
  • HY-181489
    SARS-CoV-2 3CLpro-IN-35 3023042-32-9
    SARS-CoV-2 3CLpro-IN-35 is a SARS-CoV-2 3CLpro inhibitor with an IC50 of 0.15 μM. SARS-CoV-2 3CLpro-IN-35 inhibits the proliferation of bladder cancer cells, exerts anti-SARS-CoV-2 activity, and exhibits low cytotoxicity in fibroblasts. SARS-CoV-2 3CLpro-IN-35 is applicable to research related to SARS-CoV-2 infection and bladder cancer.
    SARS-CoV-2 3CLpro-IN-35
  • HY-181517
    Antitumor agent-212 3108305-08-1
    Antitumor agent-212 is a α-exo-methylene-selenolactone derivative with prominent selective antitumor activity. Antitumor agent-212 exhibits an MIC value of 128 μg/mL against Gram-positive bacteria. Antitumor agent-212 exhibits significant antitumor effects in the U87 human glioma xenograft model. Antitumor agent-212 can be used for the study of glioma, breast cancer and non-small cell lung cancer, and antibacterial study.
    Antitumor agent-212
  • HY-181643
    YOK24 3075693-57-8 98%
    YOK24 is an orally active MetAP2 inhibitor and anti-amoebic agent. YOK24 binds covalently to MetAP2 and inhibits its peptidase activity, where MetAP2 is a protein essential for the proliferation of *Entamoeba histolytica*. YOK24 can be used in the research of amoebiasis.
    YOK24
  • HY-181644
    NS-181 3075693-63-6 98%
    NS-181 is an orally active MetAP2 inhibitor and antiamebic agent with oral effectiveness.NS-181 functionally inhibits methionine aminopeptidase 2, a protein critical for Entamoeba histolytica proliferation. NS-181 exerts antiamebic activity against Entamoeba histolytica, leading to resolution of amebic liver abscess. NS-181 can be used for the research of amebiasis.
    NS-181
  • HY-181661
    YL1004
    YL1004 is a potent, selective and orally active noncovalent inhibitor of SARS-CoV-2 papain-like protease (PLpro). YL1004 shows an IC50 of 17.5 nM and a Ki of 2.3 nM against PLpro, with an in vitro anti-SARS-CoV-2 EC50 of 0.08 μM-1.37 μM. YL1004 suppresses the proteolytic activity of PLpro and blocks its deubiquitinating and deISGylating effects to restore host innate antiviral immune signaling. YL1004 inhibits the replication of wild-type, Delta, Omicron variants and nirmatrelvir-resistant strains of SARS-CoV-2. YL1004 can be used for the research of COVID-19 (SARS-CoV-2 infection).
    YL1004
  • HY-181691
    JAK2-IN-20 98%
    JAK2-IN-20 is an orally active dual inhibitor targeting JAK2 kinase (IC50=49.17 nM) and influenza A virus PB2 protein (IC50=3.337 μM, Kd=2.82 μM). JAK2-IN-20 effectively blocks the JAK/STAT signaling pathway by reducing the phosphorylation levels of STAT1 and STAT3, thereby inhibiting viral replication and downregulating the expression of viral NP and PB2 proteins. In addition, JAK2-IN-20 significantly inhibits the mRNA expression of key inflammatory cytokines such as IL-6, TNF-α and IFN-β in inflammation and influenza infection models. JAK2-IN-20 serves as an important tool molecule for the study of influenza A virus infection and related pathologies.
    JAK2-IN-20
  • HY-181751
    FabI-IN-1
    FabI-IN-1 is a FabI (enoyl-acyl carrier protein reductase) inhibitor with a Ki of 0.32 μM against E. coli FabI. FabI-IN-1 inhibits exhibits activity against Gram-negative bacteria including Escherichia coli (MIC = 6.25 μM) and Klebsiella pneumoniae. FabI-IN-1 rescues Galleria mellonella larvae from lethal Escherichia coli infection. FabI-IN-1 exerts a synergistic effect with Colistin (HY-113678) against Escherichia coli. FabI-IN-1 can be used for the research of gram-negative bacterial infection.
    FabI-IN-1
  • HY-181770
    PDE4B-IN-7 1226697-79-5 98%
    PDE4B-IN-7 is a PDE-4B inhibitor with an IC50 of 160 nM. PDE4B-IN-7 can form a firm and stable binding with the active site of PDE-4B. PDE4B-IN-7 inhibits acetylcholine-induced bronchospasm in guinea pigs. PDE4B-IN-7 exerts activity against susceptible Gram-positive and Gram-negative bacterial strains. PDE4B-IN-7 can be used for the researches of asthma and bacterial agent.
    PDE4B-IN-7
  • HY-181778
    RdRP-IN-10 3099256-57-9 98%
    RdRP-IN-10 is a SARS-CoV-2 RNA-dependent RNA polymerase (RdRp) inhibitor with an IC50 value of 5.78 μM. RdRP-IN-10 forms covalent binds with SARS-CoV-2 nsp8 Cys114, disrupts nsp8-nsp12 stabilizing interactions. RdRP-IN-10 inhibits SARS-CoV-2 RdRp-mediated RNA polymerization without interfering with RNA-RdRp complex binding. RdRP-IN-10 exerts antiviral effects in cellular models. RdRP-IN-10 can be used for the research of SARS-CoV-2 infection.
    RdRP-IN-10
  • HY-181785
    Influenza A virus-IN-18 3085746-63-7
    Influenza A virus-IN-18 (Compound C2e) is an orally active inhibitor of Influenza A virus (IC50: 2.5 μM against PR8/H1N1; 6.42 μM against H3N2). Influenza A virus-IN-18 binds directly to the H1N1/PR8 HA protein with high affinity, with a KD of 0.25 μM. Influenza A virus-IN-18 is applicable to research related to Influenza A virus infection.
    Influenza A virus-IN-18
  • HY-181824
    Cholera toxin-IN-1
    Cholera toxin-IN-1 is a potent competitive inhibitor of cholera toxin B subunit (CTB) with an IC50 value of 11.78 μM. Cholera toxin-IN-1 forms stable hydrogen bonds and hydrophobic interactions. Cholera toxin-IN-1 competitively blocks the binding of CTB to GM1 ganglioside. Cholera toxin-IN-1 can be used for the research of cholera.
    Cholera toxin-IN-1
  • HY-181885
    Antiviral agent 80 3110745-57-5
    Antiviral agent 80 is a conjugate of Zanamivir (HY-13210) and Amantadine (HY-13317), acting as a dual inhibitor of influenza virus M2 ion channel/neuraminidase (NA). Antiviral agent 80 exhibits potent inhibitory activity against both wild-type and drug-resistant influenza neuraminidase mutants, with an IC50 value range of 1.50 nM to 120.4 nM. Antiviral agent 80 can be used in influenza-related research.
    Antiviral agent 80
  • HY-181904
    SARS-CoV-2 Mpro ligand 2 98%
    SARS-CoV-2 Mpro ligand 2 (Compound 24) is a ligand for the target protein for PROTAC (SARS-CoV-2 Mpro). SARS-CoV-2 Mpro ligand 2 can be used to synthesize PROTAC SARS-CoV-2 Mpro degrader-8 (HY-181870).
    SARS-CoV-2 Mpro ligand 2
  • HY-181905
    (S,R,S)-AHPC-Me-C2-piperazine 2715987-83-8
    (S,R,S)-AHPC-Me-C2-piperazine is an E3 ligase ligand-linker conjugate containing an E3 ligase ligand (HY-112078) and a PROTAC linker. (S,R,S)-AHPC-Me-C2-piperazine can be used in the PROTAC SARS-CoV-2 Mpro degrader-8 (HY-181870).
    (S,R,S)-AHPC-Me-C2-piperazine
  • HY-181966
    Sideromycin 7 98%
    Sideromycin 7 is an antibacterial agent. Sideromycin 7 forms a 7-Bi3+ coordination complex with bismuth citrate, exerting a three-pronged antibacterial mode of action: direct DNA binding to induce damage and arrest replication, suppression of KdpC synthesis to block KdpFABC-mediated potas-sium transport, and inhibition of ATP production. Sideromycin 7 exhibits potent antibacterial activity against Ciprofloxacin (HY-B0356)-resistant Pseudomonas aeruginosa strains. Sideromycin 7 exerts antibiofilm activity against Pseudomonas aeruginosa. Sideromycin 7 can be used for the research of ciprofloxacin-resistant Pseudomonas aeruginosa infection.
    Sideromycin 7
  • HY-181969
    BFB78
    BFB78 is a blood-brain barrier-permeable nsP2 protease inhibitor. BFB78 potently and broadly inhibits the purified nsP2 proteases of various alphaviruses, with IC50 values ranging from 21.6 nM (Mayaro virus; MAYV) to 130.7 nM (Chikungunya virus; CHIKV). BFB78 blocks viral replication in cell culture systems and reduces viral titers in the brains of mice. BFB78 can be used in studies related to Venezuelan equine encephalitis virus (VEEV) infection.
    BFB78
  • HY-181983
    VPC285785 2759276-10-1 98%
    VPC285785 is an orally active SARS-CoV-2 main protease inhibitor with an IC50 of 0.8 μM and a Kd of 2.7 μM. VPC285785 functionally inhibits the viral main protease-mediated processing of viral polyprotein precursors required for viral replication. VPC285785 reduces viral loads in the liver, brain and spleen tissues of MHV-infected mice. VPC285785 is applicable to the research of coronavirus infections.
    VPC285785
Cat. No. Product Name / Synonyms Application Reactivity